CVM vs. ADAP, IPSC, MGX, ZURA, IPHA, CADL, IVVD, GNFT, CHRS, and CGEN
Should you be buying CEL-SCI stock or one of its competitors? The main competitors of CEL-SCI include Adaptimmune Therapeutics (ADAP), Century Therapeutics (IPSC), Metagenomi (MGX), Zura Bio (ZURA), Innate Pharma (IPHA), Candel Therapeutics (CADL), Invivyd (IVVD), Genfit (GNFT), Coherus BioSciences (CHRS), and Compugen (CGEN). These companies are all part of the "biological products, except diagnostic" industry.
CEL-SCI (NYSE:CVM) and Adaptimmune Therapeutics (NASDAQ:ADAP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, community ranking, earnings and analyst recommendations.
12.1% of CEL-SCI shares are held by institutional investors. Comparatively, 31.4% of Adaptimmune Therapeutics shares are held by institutional investors. 16.2% of CEL-SCI shares are held by insiders. Comparatively, 12.4% of Adaptimmune Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Adaptimmune Therapeutics has a consensus price target of $2.79, indicating a potential upside of 175.99%. Given Adaptimmune Therapeutics' higher probable upside, analysts plainly believe Adaptimmune Therapeutics is more favorable than CEL-SCI.
In the previous week, Adaptimmune Therapeutics had 6 more articles in the media than CEL-SCI. MarketBeat recorded 6 mentions for Adaptimmune Therapeutics and 0 mentions for CEL-SCI. Adaptimmune Therapeutics' average media sentiment score of 0.75 beat CEL-SCI's score of 0.00 indicating that Adaptimmune Therapeutics is being referred to more favorably in the news media.
CEL-SCI has a net margin of 0.00% compared to Adaptimmune Therapeutics' net margin of -890.13%. CEL-SCI's return on equity of -218.00% beat Adaptimmune Therapeutics' return on equity.
CEL-SCI has higher earnings, but lower revenue than Adaptimmune Therapeutics. CEL-SCI is trading at a lower price-to-earnings ratio than Adaptimmune Therapeutics, indicating that it is currently the more affordable of the two stocks.
Adaptimmune Therapeutics received 309 more outperform votes than CEL-SCI when rated by MarketBeat users. Likewise, 62.55% of users gave Adaptimmune Therapeutics an outperform vote while only 0.00% of users gave CEL-SCI an outperform vote.
CEL-SCI has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500. Comparatively, Adaptimmune Therapeutics has a beta of 2.44, meaning that its share price is 144% more volatile than the S&P 500.
Summary
Adaptimmune Therapeutics beats CEL-SCI on 11 of the 16 factors compared between the two stocks.
Get CEL-SCI News Delivered to You Automatically
Sign up to receive the latest news and ratings for CVM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CVM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
